J&J Says 30,000-40,000 Patients Are On Standby For Cypher Approval
This article was originally published in The Gray Sheet
Executive SummaryInterventional cardiologists are delaying a significant number of conventional stenting procedures as they anticipate near-term FDA approval of Johnson & Johnson's sirolimus-eluting Cypher stent
You may also be interested in...
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.